Get the Stockscreener App
8.37
2.45%
0.20
Pre-market:
8.43
0.06
+0.72%
Anavex Life Sciences Corporation stock is traded at $8.37, with a volume of 690.24K.
It is up +2.45% in the last 24 hours and down -8.22% over the past month.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
See More
Previous Close:
$8.17
Open:
$8.23
24h Volume:
690.24K
Relative Volume:
0.70
Market Cap:
$714.55M
Revenue:
-
Net Income/Loss:
$-43.16M
P/E Ratio:
-15.22
EPS:
-0.55
Net Cash Flow:
$-29.31M
1W Performance:
-2.22%
1M Performance:
-8.22%
6M Performance:
+12.42%
1Y Performance:
+86.41%
1-Day Range:
$7.975
$8.4126
1-Week Range:
$7.975
$8.68
52-Week Range:
$3.51
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
8.37 | 728.15M | 0 | -43.16M | -29.31M | -0.55 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 38.69M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
69.53 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Tower Research Capital LLC TRC Buys 1,708 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2025 Earnings Call Transcript - Insider Monkey
Anavex Life Sciences to Participate at Upcoming Healthcare Confe - GuruFocus
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences - The Manila Times
Anavex Brings Alzheimer's and Parkinson's Drug Updates to Prestigious Wainwright Healthcare Conferences - Stock Titan
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot - CT Insider
Raymond James Financial Inc. Makes New $167,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Reports Q2 2025 Financial Results - TipRanks
Earnings call transcript: Anavex Life Sciences Q2 2025 reports net loss, stock rises - Investing.com Nigeria
Anavex Life Sciences (AVXL) Q2 Earnings Exceed Expectations - GuruFocus
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financia - GuruFocus
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update - The Manila Times
Anavex Life Sciences Corp. Reports Q2 Fiscal 2025 Financial Results and Updates on Clinical Developments - Nasdaq
Anavex Life Sciences Corp. Q2 Loss Beats Estimates - Nasdaq
Anavex Life Sciences Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Closing Bell Recap: Anavex Life Sciences Corporation (AVXL) Ends at 8.91, Reflecting a -4.81 Downturn - DWinneX
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Fina - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 | AVXL Stock News - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - The Manila Times
Anavex Life Sciences Corp. to Announce Second Fiscal Quarter Financial Results on May 13, 2025 - Nasdaq
Anavex Life Sciences Earnings Preview: Key Updates Coming on Alzheimer's and Rare Disease Programs - Stock Titan
Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World
Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com
Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference - The Manila Times
Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan
Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Lost Money on Anavex Life Sciences Corp.(AVXL)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - ACCESS Newswire
Anavex Life Sciences Corporation’s Market Journey: Closing Strong at 9.31, Up 1.09 - DWinneX
Buying Buzz: Anavex Life Sciences Corporation [AVXL] Director Donhauser Peter D.O. purchases 2,835 shares of the company – Knox Daily - knoxdaily.com
AVXL overperforms with a 5.14 increase in share price - uspostnews.com
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board - The Manila Times
Harvard-Trained Alzheimer's Pioneer With 35,000-Patient Database Strengthens Anavex's Scientific Team - Stock Titan
Anavex Life Sciences Appoints Dr. Audrey Gabelle, MD, PhD To Scientific Advisory Board - citybiz
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer’s Data ... By GuruFocus - Investing.com Canada
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by LPL Financial LLC - Defense World
Anavex Life Sciences Presents Novel Alzheimer Treatment Research at International Conference in Abu Dhabi - Nasdaq
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East - TradingView
Anavex Life Sciences Announces Presentation at 9th International - GuruFocus
Geode Capital Management LLC Has $20.14 Million Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.17%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):